Flex Drug Patent Portfolio
Flex owns 1 orange book drug protected by 4 US patents Given below is the list of Flex's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11559485 | Orally Disintegrating Tablet Comprising Amorphous Solid Dispersion Of Nilotinib | 30 Apr, 2041 | Active |
| US11389450 | Amorphous Nilotinib Microparticles And Uses Thereof | 29 Jan, 2041 | Active |
| US12016861 | Amorphous Nilotinib Microparticles And Uses Thereof | 29 Jan, 2041 | Active |
| US12029740 | Amorphous Nilotinib Microparticles And Uses Thereof | 29 Jan, 2041 | Active |
Flex's Family Patents
Flex Drug List
Given below is the complete list of Flex's drugs and the patents protecting them.
1. Cavhanza
Cavhanza is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11559485 | Orally Disintegrating Tablet Comprising Amorphous Solid Dispersion Of Nilotinib |
30 Apr, 2041
(14 years from now)
| Active |
| US11389450 | Amorphous Nilotinib Microparticles And Uses Thereof |
29 Jan, 2041
(14 years from now)
| Active |
| US12016861 | Amorphous Nilotinib Microparticles And Uses Thereof |
29 Jan, 2041
(14 years from now)
| Active |
| US12029740 | Amorphous Nilotinib Microparticles And Uses Thereof |
29 Jan, 2041
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cavhanza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List